Effects of metyrapone in patients with mild hypercortisolism
Authors' conclusion
Low-dose evening metyrapone appears to be a safe and potentially effective option for improving BP control in patients with mH, especially those with higher baseline systolic pressure.
Study context
- Population
- Patients with mild hypercortisolism (cortisol >1.8 µg/dL after 1 mg dexamethasone suppression, <2 specific Cushing syndrome symptoms) with hypertension or glucose metabolism impairment
- Participants
- 20 patients
- Outcome
- Predefined clinically significant BP improvement (≥5 mmHg reduction in mean 24-h systolic BP without therapy escalation)
- Follow-up
- 24 weeks
Methodological detailssingle-centre, single-arm
- Single-centre
- Single-arm
Main finding
As reported in the abstract
Clinically significant BP improvement (≥5 mmHg reduction in mean 24-h systolic BP without therapy escalation)
Patients achieving predefined clinically significant blood pressure (BP) improvement
40%
8/20
Observational data: associations, not effects.
Further findings
Patients
- Glucometabolic control improved, notably in T2D
- 4
- HbA1c reduction ≥ 0.5% without changes in antidiabetic therapy
- 2
Safety
| Outcome | Values |
|---|---|
| Adverse events and adrenal insufficiency | Metyrapone 0 events |
- Adverse events and adrenal insufficiency — Metyrapone was well tolerated; no adverse events or adrenal insufficiency reported
- 0
Original publication
Effects of metyrapone in patients with mild hypercortisolism. Eur J Endocrinol. Published 16 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →